The veterans affairs implantable insulin pump study

Effect on cardiovascular risk factors

William C. Duckworth, Christopher D. Saudek, Anita Giobbie-Hurder, William G. Henderson, Robert R. Henry, David E. Kelley, Steven V. Edelman, Franklin J. Zieve, Robert A. Adler, James W. Anderson, Robert J. Anderson, Bruce P. Hamilton, Thomas W. Donner, M. Sue Kirkman, Nancy A. Morgan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

OBJECTIVE - To determine whether implantable insulin pump (IIP) and multiple-dose insulin (MDI) therapy have different effects on cardiovascular risk factors in insulin-requiring patients with type 2 diabetes. RESEARCH DESIGN AND METHODS - A randomized clinical trial was conducted at seven Veterans Affairs medical centers in 121 male patients with type 2 diabetes between the ages of 40 and 69 years receiving at least one injection of insulin per day and with HbA(1c) levels of ≤8% at baseline. Weights, blood pressures, insulin use, and glucose monitoring data were obtained at each visit. Lipid levels were obtained at 0, 4, 8, and 12 months, and free and total insulin levels were obtained at 0, 6, and 12 months. All medications being taken were recorded at each visit. RESULTS - No difference in absolute blood pressure, neither systolic nor diastolic, was seen between patients receiving MDI or IIP therapy, but significantly more MDI patients require anti-hypertensive medications. When blood pressure was modeled against weight and time, IIP therapy was significantly better than MDI therapy for systolic blood pressure in patients with BMI 34 kg/m2. Total cholesterol levels decreased in the overall sample, but IIP patients exhibited significantly higher levels than MDI patients. Triglyceride levels increased over time for both groups, with IIP patients having significantly higher levels than patients in the MDI group. BMI was a significant predictor of, and inversely proportional to, HDL cholesterol level. No difference in lipid-lowering drug therapy was seen between the two groups. Free insulin and insulin antibodies tended to decrease in the IIP group as compared with the MDI group. C-peptide levels decreased in both groups. CONCLUSIONS - IIP therapy in insulin-requiring patients with type 2 diabetes has advantages over MDI therapy in decreasing the requirement for antihypertensive therapy and for decreasing total and free insulin and insulin antibodies. Both therapies reduce total cholesterol and C-peptide levels.

Original languageEnglish
Pages (from-to)1596-1602
Number of pages7
JournalDiabetes Care
Volume21
Issue number10
DOIs
StatePublished - 1998

Fingerprint

Veterans
Insulin
Blood Pressure
Type 2 Diabetes Mellitus
Insulin Antibodies
C-Peptide
Therapeutics
Antihypertensive Agents
Cholesterol
Lipids
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Duckworth, W. C., Saudek, C. D., Giobbie-Hurder, A., Henderson, W. G., Henry, R. R., Kelley, D. E., ... Morgan, N. A. (1998). The veterans affairs implantable insulin pump study: Effect on cardiovascular risk factors. Diabetes Care, 21(10), 1596-1602. https://doi.org/10.2337/diacare.21.10.1596

The veterans affairs implantable insulin pump study : Effect on cardiovascular risk factors. / Duckworth, William C.; Saudek, Christopher D.; Giobbie-Hurder, Anita; Henderson, William G.; Henry, Robert R.; Kelley, David E.; Edelman, Steven V.; Zieve, Franklin J.; Adler, Robert A.; Anderson, James W.; Anderson, Robert J.; Hamilton, Bruce P.; Donner, Thomas W.; Sue Kirkman, M.; Morgan, Nancy A.

In: Diabetes Care, Vol. 21, No. 10, 1998, p. 1596-1602.

Research output: Contribution to journalArticle

Duckworth, WC, Saudek, CD, Giobbie-Hurder, A, Henderson, WG, Henry, RR, Kelley, DE, Edelman, SV, Zieve, FJ, Adler, RA, Anderson, JW, Anderson, RJ, Hamilton, BP, Donner, TW, Sue Kirkman, M & Morgan, NA 1998, 'The veterans affairs implantable insulin pump study: Effect on cardiovascular risk factors', Diabetes Care, vol. 21, no. 10, pp. 1596-1602. https://doi.org/10.2337/diacare.21.10.1596
Duckworth WC, Saudek CD, Giobbie-Hurder A, Henderson WG, Henry RR, Kelley DE et al. The veterans affairs implantable insulin pump study: Effect on cardiovascular risk factors. Diabetes Care. 1998;21(10):1596-1602. https://doi.org/10.2337/diacare.21.10.1596
Duckworth, William C. ; Saudek, Christopher D. ; Giobbie-Hurder, Anita ; Henderson, William G. ; Henry, Robert R. ; Kelley, David E. ; Edelman, Steven V. ; Zieve, Franklin J. ; Adler, Robert A. ; Anderson, James W. ; Anderson, Robert J. ; Hamilton, Bruce P. ; Donner, Thomas W. ; Sue Kirkman, M. ; Morgan, Nancy A. / The veterans affairs implantable insulin pump study : Effect on cardiovascular risk factors. In: Diabetes Care. 1998 ; Vol. 21, No. 10. pp. 1596-1602.
@article{fba9f9f8e4414ca6b71f78aaff865dd9,
title = "The veterans affairs implantable insulin pump study: Effect on cardiovascular risk factors",
abstract = "OBJECTIVE - To determine whether implantable insulin pump (IIP) and multiple-dose insulin (MDI) therapy have different effects on cardiovascular risk factors in insulin-requiring patients with type 2 diabetes. RESEARCH DESIGN AND METHODS - A randomized clinical trial was conducted at seven Veterans Affairs medical centers in 121 male patients with type 2 diabetes between the ages of 40 and 69 years receiving at least one injection of insulin per day and with HbA(1c) levels of ≤8{\%} at baseline. Weights, blood pressures, insulin use, and glucose monitoring data were obtained at each visit. Lipid levels were obtained at 0, 4, 8, and 12 months, and free and total insulin levels were obtained at 0, 6, and 12 months. All medications being taken were recorded at each visit. RESULTS - No difference in absolute blood pressure, neither systolic nor diastolic, was seen between patients receiving MDI or IIP therapy, but significantly more MDI patients require anti-hypertensive medications. When blood pressure was modeled against weight and time, IIP therapy was significantly better than MDI therapy for systolic blood pressure in patients with BMI 34 kg/m2. Total cholesterol levels decreased in the overall sample, but IIP patients exhibited significantly higher levels than MDI patients. Triglyceride levels increased over time for both groups, with IIP patients having significantly higher levels than patients in the MDI group. BMI was a significant predictor of, and inversely proportional to, HDL cholesterol level. No difference in lipid-lowering drug therapy was seen between the two groups. Free insulin and insulin antibodies tended to decrease in the IIP group as compared with the MDI group. C-peptide levels decreased in both groups. CONCLUSIONS - IIP therapy in insulin-requiring patients with type 2 diabetes has advantages over MDI therapy in decreasing the requirement for antihypertensive therapy and for decreasing total and free insulin and insulin antibodies. Both therapies reduce total cholesterol and C-peptide levels.",
author = "Duckworth, {William C.} and Saudek, {Christopher D.} and Anita Giobbie-Hurder and Henderson, {William G.} and Henry, {Robert R.} and Kelley, {David E.} and Edelman, {Steven V.} and Zieve, {Franklin J.} and Adler, {Robert A.} and Anderson, {James W.} and Anderson, {Robert J.} and Hamilton, {Bruce P.} and Donner, {Thomas W.} and {Sue Kirkman}, M. and Morgan, {Nancy A.}",
year = "1998",
doi = "10.2337/diacare.21.10.1596",
language = "English",
volume = "21",
pages = "1596--1602",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "10",

}

TY - JOUR

T1 - The veterans affairs implantable insulin pump study

T2 - Effect on cardiovascular risk factors

AU - Duckworth, William C.

AU - Saudek, Christopher D.

AU - Giobbie-Hurder, Anita

AU - Henderson, William G.

AU - Henry, Robert R.

AU - Kelley, David E.

AU - Edelman, Steven V.

AU - Zieve, Franklin J.

AU - Adler, Robert A.

AU - Anderson, James W.

AU - Anderson, Robert J.

AU - Hamilton, Bruce P.

AU - Donner, Thomas W.

AU - Sue Kirkman, M.

AU - Morgan, Nancy A.

PY - 1998

Y1 - 1998

N2 - OBJECTIVE - To determine whether implantable insulin pump (IIP) and multiple-dose insulin (MDI) therapy have different effects on cardiovascular risk factors in insulin-requiring patients with type 2 diabetes. RESEARCH DESIGN AND METHODS - A randomized clinical trial was conducted at seven Veterans Affairs medical centers in 121 male patients with type 2 diabetes between the ages of 40 and 69 years receiving at least one injection of insulin per day and with HbA(1c) levels of ≤8% at baseline. Weights, blood pressures, insulin use, and glucose monitoring data were obtained at each visit. Lipid levels were obtained at 0, 4, 8, and 12 months, and free and total insulin levels were obtained at 0, 6, and 12 months. All medications being taken were recorded at each visit. RESULTS - No difference in absolute blood pressure, neither systolic nor diastolic, was seen between patients receiving MDI or IIP therapy, but significantly more MDI patients require anti-hypertensive medications. When blood pressure was modeled against weight and time, IIP therapy was significantly better than MDI therapy for systolic blood pressure in patients with BMI 34 kg/m2. Total cholesterol levels decreased in the overall sample, but IIP patients exhibited significantly higher levels than MDI patients. Triglyceride levels increased over time for both groups, with IIP patients having significantly higher levels than patients in the MDI group. BMI was a significant predictor of, and inversely proportional to, HDL cholesterol level. No difference in lipid-lowering drug therapy was seen between the two groups. Free insulin and insulin antibodies tended to decrease in the IIP group as compared with the MDI group. C-peptide levels decreased in both groups. CONCLUSIONS - IIP therapy in insulin-requiring patients with type 2 diabetes has advantages over MDI therapy in decreasing the requirement for antihypertensive therapy and for decreasing total and free insulin and insulin antibodies. Both therapies reduce total cholesterol and C-peptide levels.

AB - OBJECTIVE - To determine whether implantable insulin pump (IIP) and multiple-dose insulin (MDI) therapy have different effects on cardiovascular risk factors in insulin-requiring patients with type 2 diabetes. RESEARCH DESIGN AND METHODS - A randomized clinical trial was conducted at seven Veterans Affairs medical centers in 121 male patients with type 2 diabetes between the ages of 40 and 69 years receiving at least one injection of insulin per day and with HbA(1c) levels of ≤8% at baseline. Weights, blood pressures, insulin use, and glucose monitoring data were obtained at each visit. Lipid levels were obtained at 0, 4, 8, and 12 months, and free and total insulin levels were obtained at 0, 6, and 12 months. All medications being taken were recorded at each visit. RESULTS - No difference in absolute blood pressure, neither systolic nor diastolic, was seen between patients receiving MDI or IIP therapy, but significantly more MDI patients require anti-hypertensive medications. When blood pressure was modeled against weight and time, IIP therapy was significantly better than MDI therapy for systolic blood pressure in patients with BMI 34 kg/m2. Total cholesterol levels decreased in the overall sample, but IIP patients exhibited significantly higher levels than MDI patients. Triglyceride levels increased over time for both groups, with IIP patients having significantly higher levels than patients in the MDI group. BMI was a significant predictor of, and inversely proportional to, HDL cholesterol level. No difference in lipid-lowering drug therapy was seen between the two groups. Free insulin and insulin antibodies tended to decrease in the IIP group as compared with the MDI group. C-peptide levels decreased in both groups. CONCLUSIONS - IIP therapy in insulin-requiring patients with type 2 diabetes has advantages over MDI therapy in decreasing the requirement for antihypertensive therapy and for decreasing total and free insulin and insulin antibodies. Both therapies reduce total cholesterol and C-peptide levels.

UR - http://www.scopus.com/inward/record.url?scp=17944384073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17944384073&partnerID=8YFLogxK

U2 - 10.2337/diacare.21.10.1596

DO - 10.2337/diacare.21.10.1596

M3 - Article

VL - 21

SP - 1596

EP - 1602

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 10

ER -